Why the study?
Antiplatelet therapy reduces vascular events in established atherosclerotic cardiovascular disease, but knowledge regarding the extent and determinants of its use is limited.
What are the rates and determinants of antiplatelet therapy use for secondary prevention following acute ASCVD events?
Population
150 728 adults hospitalised for an acute ASCVD event in Scotland
Comparison
APT use across MI, ischaemic stroke, and PAD
Design
Retrospective cohort study
Authors
Loading...
Gaps in APT initiation after ASCVD events, especially among women and PAD patients, should not yet change practice; leaves open targeted quality improvement research.
What are the rates and determinants of antiplatelet therapy use for secondary prevention following acute ASCVD events?
There are significant gaps in the initiation and continuation of antiplatelet therapy for secondary ASCVD prevention, disproportionately affecting women, older adults, and patients with PAD or stroke.
Thalmann et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: